Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?

Clinical transplants

Volumn , Issue , 2009, Pages 425-429

  Lee, Iris ^a   Constantinescu, Serban ^b   Gillespie, Avrum ^b   Swami, Abhishek ^b   Birkenbach, Mark ^b   Leech, Stephen ^b   Silva, Patricio ^b   Karachristos, Andreas ^b   Daller, John A ^b   Sifontis, Nicole M ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; CREATININE; IMMUNOGLOBULIN; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ARTICLE; B LYMPHOCYTE; BLOOD; CASE REPORT; CELLULAR IMMUNITY; CHRONIC KIDNEY FAILURE; FOLLOW UP; GRAFT REJECTION; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; T LYMPHOCYTE;

B-LYMPHOCYTES; BORONIC ACIDS; CREATININE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEASE INHIBITORS; PYRAZINES; T-LYMPHOCYTES;

EID: 77954582214     PISSN: 08909016     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)